Nevertheless, this success cannot be replicated in pancreatic cancer because multiple phase III trials with anti-VEGF agents have failed to increase the overall survival of advanced pancreatic cancer patients compared to chemotherapy alone [114]. This evidence concerns the gene VEGFA and familial pancreatic carcinoma.